Clinical trials · Arkansas
Duchenne Muscular Dystrophy clinical trials in Arkansas
We’re tracking 13 recruiting duchenne muscular dystrophy studies with a site in Arkansas — including Phase 1, Phase 1/Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Arkansas
- NCT07160634RecruitingPhase 3
Gene therapy for ambulant males with Duchenne muscular dystrophy
This trial tests a new gene therapy called SGT-003 in boys and men with Duchenne muscular dystrophy who are still able to walk. The treatment aims to deliver a working version of the dystrophin gene to help muscle cells produce the protein they are missing.
Little Rock, ArkansasAges 7–11 - NCT06564974Recruiting
Long-term safety study of Agamree for Duchenne muscular dystrophy
This study watches boys with Duchenne muscular dystrophy who are already taking Agamree (vamorolone) to see how safe it is over a long period. It helps doctors understand the medicine's effects over time.
Little Rock, ArkansasAges 2 years+ - NCT04626674RecruitingPhase 1
Gene therapy safety study for non-ambulatory Duchenne
This Phase 1 trial studies a one-time gene therapy treatment (SRP-9001) to see if it is safe and whether it can produce the needed gene activity in people with Duchenne muscular dystrophy (DMD) who are not walking. It may help researchers understand whether this approach could be useful for DMD patients, especially in later stages.
Little Rock, ArkansasAges 2 years+ - NCT04906460RecruitingPhase 1/Phase 2
Testing WVE-N531 for Duchenne muscular dystrophy exon 53
This early-phase study tests WVE-N531 in people with Duchenne muscular dystrophy (DMD) whose genetics specifically match an “exon 53” change. It may help by targeting the muscle disease process, and it includes procedures like muscle biopsies and regular heart/lung checks.
Little Rock, ArkansasAges 4–18 - NCT06138639RecruitingPhase 1/Phase 2
Gene therapy SGT-003 for Duchenne muscular dystrophy
This trial tests a new gene therapy called SGT-003 for children with Duchenne muscular dystrophy. It aims to help the body produce a working version of dystrophin, the protein missing in Duchenne.
Little Rock, ArkansasAges birth–17 years - NCT06817382RecruitingPhase 1
Gene therapy for young boys with Duchenne muscular dystrophy
This study tests a one-time gene therapy given by injection into the spinal fluid (intrathecal) for boys with Duchenne muscular dystrophy. It aims to see if the treatment is safe and how it spreads in the body, and may offer a new way to slow the disease.
Little Rock, ArkansasAges 2–4 - NCT07127978Recruiting
Study of Givinostat in people with Duchenne muscular dystrophy
This study is for people with Duchenne muscular dystrophy (DMD) who are taking Givinostat, a daily oral medicine. Researchers will look at real-world data to see how the medicine works in everyday life, including lab results and how it's being used.
Little Rock, ArkansasAges 6 years+ - NCT07429240RecruitingPhase 1/Phase 2
Gene editing trial for Duchenne muscular dystrophy (ages 2-7)
This trial tests a new gene editing treatment called PBGENE-DMD for boys with Duchenne muscular dystrophy (DMD) whose genetic mutation falls within a specific range of the dystrophin gene (exons 45-55). The goal is to see if it is safe and can help improve muscle function.
Little Rock, ArkansasAges 2–7 - NCT07609394Recruiting
Duchenne and Becker Muscular Dystrophy Health Records Study
This study collects electronic health records (medical information already in your doctor's computer system) from people with Duchenne or Becker muscular dystrophy, or female carriers of these conditions. Researchers will use this data to better understand the diseases and improve care over time.
Little Rock, ArkansasAges Any age - NCT06270719Enrolling by invitation
Comparing ELEVIDYS to standard care for Duchenne muscular dystrophy
This study compares the gene therapy ELEVIDYS (delandistrogene moxeparvovec) to usual treatments for people with Duchenne muscular dystrophy (DMD). It helps researchers understand how well ELEVIDYS works over time in real-world settings.
Little Rock, ArkansasAges 4 years+ - NCT06606340Enrolling by invitation
Long-term study of eteplirsen, golodirsen, or casimersen for DMD
This study follows people with Duchenne muscular dystrophy (DMD) who are taking eteplirsen, golodirsen, or casimersen. It aims to understand how these medicines work in everyday life over a long period.
Little Rock, ArkansasAges Any age - NCT06491927Enrolling by invitation
Long-term follow-up for RGX-202 in Duchenne muscular dystrophy
This long-term follow-up study watches people who previously received the experimental gene therapy RGX-202 for Duchenne muscular dystrophy. It checks how patients are doing over time and does not involve any new treatment.
Little Rock, ArkansasAges Any age - NCT05967351Enrolling by invitationPhase 3
Long-term follow-up for Duchenne patients treated before
This study checks how people with Duchenne muscular dystrophy are doing long-term after receiving delandistrogene moxeparvovec (SRP-9001) in an earlier trial. It helps researchers understand the long-term safety and effects of that treatment.
Little Rock, ArkansasAges Any age
Where these studies are running in Arkansas
Institutions with a site for the recruiting duchenne muscular dystrophy studies listed above.
- Arkansas Children's Hospital · 11 studies
- Arkansas Children's Research Institute
- USA012
What taking part in a duchenne muscular dystrophy study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Duchenne Muscular Dystrophy trials in other states
Common questions
- Are there duchenne muscular dystrophy clinical trials in Arkansas?
- Yes. We're currently tracking 13 recruiting duchenne muscular dystrophy studies with a site in Arkansas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a duchenne muscular dystrophy study in Arkansas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Arkansas to take part?
- Not necessarily. These studies have a site in Arkansas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a duchenne muscular dystrophy trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New duchenne muscular dystrophy studies open in Arkansas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.